Molecularly targeted therapy for neuroblastoma

Research output: Contribution to journalReview articlepeer-review

35 Scopus citations


Neuroblastoma is the most common extra-cranial solid tumor encountered in childhood and accounts for 15% of pediatric cancer-related deaths. Although there has been significant improvement in the outcomes for patients with high-risk disease, the therapy needed to achieve a cure is quite toxic and for those that do experience a disease recurrence, the prognosis is very dismal. Given this, there is a tremendous need for novel therapies for children with high-risk neuroblastoma and the molecular discoveries over recent years provide hope for developing new, less toxic, and potentially more efficacious treatments. Here I discuss many of the molecular aberrations identified thus far in neuroblastoma, as well as the agents in development to target these changes. The progress made in both the preclinical arena and in early phase drug development provide much promise for the future of precision medicine in neuroblastoma.

Original languageEnglish (US)
Article number142
Issue number10
StatePublished - Oct 2018

Bibliographical note

Publisher Copyright:
© 2018 by the author. Licensee MDPI, Basel, Switzerland.


  • Molecular guided therapy
  • Neuroblastoma
  • Precision medicine
  • Targeted agents


Dive into the research topics of 'Molecularly targeted therapy for neuroblastoma'. Together they form a unique fingerprint.

Cite this